Plant Name: Pleione yunnanensis
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| OPRD1; TSHR; NPSR1; CXCR1; | |
| ADORA3; ADORA2A; ADORA1; HTR2C; DRD3; DRD4; | |
| RECQL; TDP1; PLA2G1B; BLM; ADK; PIK3R1; GLO1; HPGD; MPO; AKR1B1; HSD17B2; HSD17B10; ALOX15; ALOX12; NOX4; PYGL; POLB; | |
| PTPN1; | |
| GAA; | |
| NEK6; AKT1; MET; CAMK2B; CSNK2A1; DAPK1; NEK2; FLT3; SRC; IGF1R; PTK2; AURKB; GSK3B; CDK1; MAPK1; PIM1; NUAK1; ALK; AXL; KDR; PKN1; | |
| CA14; CA3; CA7; CA5A; CA1; CA12; CA9; CA4; CA6; CA2; CA5B; | |
| ESR1; ESR2; | |
| KDM4E; | |
| MAOA; ALOX5; XDH; | |
| MMP13; MMP3; MMP2; MMP9; | |
| ELANE; | |
| BACE1; | |
| STAT6; HIF1A; NFKB1; TP53; | |
| VCP; | |
| SLC28A2; SLC28A1; SLC28A3; | |
| ABCC1; ABCG2; | |
| LMNA; MCL1; MAPT; HTT; | |
| SMN1;SMN2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Aspartic protease | BACE1 | Beta-secretase 1 | P56817 | CHEMBL4822 |
| ATP-binding cassette | ABCC1 | Multidrug resistance-associated protein 1 | P33527 | CHEMBL3004 |
| ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
| Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
| Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Cytochrome P450 family 2 | CYP2C8 | Cytochrome P450 2C8 | P10632 | CHEMBL3721 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Endoplasmic reticular retrotranslocon family | VCP | Transitional endoplasmic reticulum ATPase | P55072 | CHEMBL1075145 |
| Enzyme_unclassified | PIK3R1 | PI3-kinase p85-alpha subunit | P27986 | CHEMBL2506 |
| Enzyme_unclassified | GLO1 | Glyoxalase I | Q04760 | CHEMBL2424 |
| Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
| Enzyme_unclassified | MPO | Myeloperoxidase | P05164 | CHEMBL2439 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
| Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
| Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
| Enzyme_unclassified | PYGL | Liver glycogen phosphorylase | P06737 | CHEMBL2568 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
| Enzyme_unclassified | PLA2G1B | Phospholipase A2 group 1B | P04054 | CHEMBL4426 |
| Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
| Enzyme_unclassified | ADK | Adenosine kinase | P55263 | CHEMBL3589 |
| Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
| Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
| Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
| Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
| Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
| Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
| Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
| Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
| Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
| Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
| Metallo protease | MMP13 | Matrix metalloproteinase 13 | P45452 | CHEMBL280 |
| Metallo protease | MMP3 | Matrix metalloproteinase 3 | P08254 | CHEMBL283 |
| Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
| Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
| Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
| Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
| Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
| Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
| Peptide receptor (family A GPCR) | OPRD1 | Delta opioid receptor | P41143 | CHEMBL236 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
| Peptide receptor (family A GPCR) | CXCR1 | Interleukin-8 receptor A | P25024 | CHEMBL4029 |
| Protein Kinase | PTK2 | Focal adhesion kinase 1 | Q05397 | CHEMBL2695 |
| Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
| Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
| Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
| Protein Kinase | NUAK1 | NUAK family SNF1-like kinase 1 | O60285 | CHEMBL5784 |
| Protein Kinase | ALK | ALK tyrosine kinase receptor | Q9UM73 | CHEMBL4247 |
| Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
| Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
| Protein Kinase | PKN1 | Protein kinase N1 | Q16512 | CHEMBL3384 |
| Protein Kinase | NEK6 | Serine/threonine-protein kinase NEK6 | Q9HC98 | CHEMBL4309 |
| Protein Kinase | AKT1 | Serine/threonine-protein kinase AKT | P31749 | CHEMBL4282 |
| Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
| Protein Kinase | CAMK2B | CaM kinase II beta | Q13554 | CHEMBL4121 |
| Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
| Protein Kinase | DAPK1 | Death-associated protein kinase 1 | P53355 | CHEMBL2558 |
| Protein Kinase | NEK2 | Serine/threonine-protein kinase NEK2 | P51955 | CHEMBL3835 |
| Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
| Protein Kinase | SRC | Tyrosine-protein kinase SRC | P12931 | CHEMBL267 |
| Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
| Protein Phosphatase | PTPN1 | Protein-tyrosine phosphatase 1B | P18031 | CHEMBL335 |
| Serine protease | ELANE | Leukocyte elastase | P08246 | CHEMBL248 |
| SLC superfamily of solute carriers | SLC28A2 | Sodium/nucleoside cotransporter 2 | O43868 | CHEMBL5780 |
| SLC superfamily of solute carriers | SLC28A1 | Sodium/nucleoside cotransporter 1 | O00337 | CHEMBL5551 |
| SLC superfamily of solute carriers | SLC28A3 | Solute carrier family 28 member 3 | Q9HAS3 | CHEMBL5707 |
| Small molecule receptor (family A GPCR) | ADORA3 | Adenosine A3 receptor | P0DMS8 | CHEMBL256 |
| Small molecule receptor (family A GPCR) | ADORA2A | Adenosine A2a receptor | P29274 | CHEMBL251 |
| Small molecule receptor (family A GPCR) | ADORA1 | Adenosine A1 receptor | P30542 | CHEMBL226 |
| Small molecule receptor (family A GPCR) | HTR2C | Serotonin 2c (5-HT2c) receptor | P28335 | CHEMBL225 |
| Small molecule receptor (family A GPCR) | DRD3 | Dopamine D3 receptor | P35462 | CHEMBL234 |
| Small molecule receptor (family A GPCR) | DRD4 | Dopamine D4 receptor | P21917 | CHEMBL219 |
| Transcription Factor | STAT6 | Signal transducer and activator of transcription 6 | P42226 | CHEMBL5401 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | MCL1 | Induced myeloid leukemia cell differentiation protein Mcl-1 | Q07820 | CHEMBL4361 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
| Unclassified | HTT | Huntingtin | P42858 | CHEMBL5514 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 5.125E-11 | 1.924E-08 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C8, CYP2C9, CYP3A4, NOX4 |
| MF | GO:0005488; binding | GO:0005524; ATP binding | 6.435E-11 | 2.325E-08 | ABCC1, ABCG2, ADK, AKT1, ALK, AURKB, AXL, BLM, CAMK2B, CDK1, CSNK2A1, DAPK1, FLT3, GSK3B, IGF1R, KDR, MAPK1, MET, NEK2, NEK6, NUAK1, PIM1, PKN1, PTK2, PYGL, RECQL, SRC, TP53, VCP |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 4.287E-10 | 1.167E-07 | ALOX12, ALOX15, ALOX5, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C8, CYP2C9, CYP3A4, XDH |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 5.729E-10 | 1.485E-07 | CYP1A2, CYP2C8, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 6.744E-10 | 1.688E-07 | CYP1A1, CYP1A2, CYP1B1, CYP2C8, CYP2C9 |
| MF | GO:0005488; binding | GO:0042802; identical protein binding | 6.625E-10 | 1.688E-07 | ABCG2, ADORA2A, AKT1, ALK, BLM, CAMK2B, CSNK2A1, DAPK1, DRD4, ESR1, ESR2, FLT3, HPGD, HTT, IGF1R, KDR, MAPK1, MAPT, MCL1, MET, MMP9, NFKB1, PYGL, SMN1, SMN2, STAT6, TP53, VCP, XDH |
| MF | GO:0005488; binding | GO:0020037; heme binding | 7.971E-10 | 1.950E-07 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C8, CYP2C9, CYP3A4, MPO, NOX4, SRC |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 1.213E-09 | 2.810E-07 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C8, CYP3A4 |
| MF | GO:0005488; binding | GO:0008270; zinc ion binding | 2.541E-09 | 5.425E-07 | BLM, CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, ESR1, ESR2, GLO1, MMP13, MMP2, MMP3, MMP9, PTPN1, TP53 |
| BP | Unclassified; | GO:2000021; regulation of ion homeostasis | 6.868E-09 | 1.289E-06 | ADORA1, ADORA2A, CA2, CA7, DRD3, HTR2C, HTT, KDR, NPSR1, PLA2G1B, SRC |
| BP | Unclassified; | GO:0032844; regulation of homeostatic process | 1.231E-08 | 2.016E-06 | ADORA1, ADORA2A, AURKB, CA2, CA7, DRD3, HIF1A, HTR2C, HTT, KDR, MAPK1, NEK2, NPSR1, PLA2G1B, SRC |
| BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 1.626E-08 | 2.475E-06 | ADORA2A, AURKB, CA2, CA7, DRD3, HIF1A, HTT, MAPK1, NEK2, NPSR1, PLA2G1B |
| MF | GO:0003824; catalytic activity | GO:0004674; protein serine/threonine kinase activity | 5.165E-08 | 7.073E-06 | AKT1, ALK, AURKB, CAMK2B, CDK1, CSNK2A1, DAPK1, GSK3B, MAPK1, NEK2, NEK6, NUAK1, PIM1, PKN1 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 5.215E-08 | 7.097E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2C8, CYP2C9 |
| BP | GO:0008152; metabolic process | GO:0018107; peptidyl-threonine phosphorylation | 1.189E-07 | 1.472E-05 | AKT1, CAMK2B, CDK1, CSNK2A1, GSK3B, MAPK1, PKN1 |
| BP | GO:0008152; metabolic process | GO:0018105; peptidyl-serine phosphorylation | 1.336E-07 | 1.625E-05 | AKT1, AURKB, CAMK2B, CDK1, GSK3B, MAPK1, NEK6, PKN1, SRC |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 2.751E-07 | 3.087E-05 | CYP1A2, CYP2C8, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 2.751E-07 | 3.087E-05 | CYP1A2, CYP2C8, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0006691; leukotriene metabolic process | 4.187E-07 | 4.434E-05 | ABCC1, ALOX12, ALOX15, ALOX5, PLA2G1B |
| BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 9.960E-07 | 9.639E-05 | ALOX12, ALOX15, ALOX5, HPGD |
| MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 1.181E-06 | 1.094E-04 | CYP1A1, CYP2C8, CYP3A4 |
| MF | GO:0005488; binding | GO:0002039; p53 binding | 1.306E-06 | 1.200E-04 | BLM, GSK3B, HIF1A, HTT, NUAK1, TP53 |
| BP | GO:0009987; cellular process | GO:0031334; positive regulation of protein complex assembly | 1.812E-06 | 1.607E-04 | ALOX15, ESR1, GSK3B, MAPT, MET, MMP3, SRC, TP53, VCP |
| BP | GO:0008152; metabolic process | GO:0002933; lipid hydroxylation | 2.354E-06 | 2.002E-04 | CYP1A1, CYP2C8, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 2.354E-06 | 2.002E-04 | CYP1A2, CYP2C9, CYP3A4 |
| BP | GO:0051179; localization | GO:0046903; secretion | 3.426E-06 | 2.836E-04 | ALOX5, AXL, CA2, CA9, CXCR1, DRD3, DRD4, ELANE, GAA, HIF1A, MAPK1, MMP9, MPO, NFKB1, PLA2G1B, PYGL, VCP, XDH |
| MF | GO:0060089; molecular transducer activity | GO:0001609; G-protein coupled adenosine receptor activity | 4.104E-06 | 3.274E-04 | ADORA1, ADORA2A, ADORA3 |
| BP | GO:0065007; biological regulation | GO:0000187; activation of MAPK activity | 7.237E-06 | 5.490E-04 | ALK, CDK1, DRD4, MAPK1, PKN1, PLA2G1B, PTPN1 |
| BP | GO:0009987; cellular process | GO:2001243; negative regulation of intrinsic apoptotic signaling pathway | 7.832E-06 | 5.901E-04 | AKT1, HIF1A, MCL1, MMP9, PTPN1, SRC |
| BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 9.750E-06 | 7.170E-04 | AKT1, BLM, CYP1A1, CYP1B1, ESR1, FLT3, MAPK1, NFKB1, NOX4, SRC |
| BP | GO:0009987; cellular process | GO:0000733; DNA strand renaturation | 9.779E-06 | 7.170E-04 | BLM, RECQL, TP53 |
| BP | GO:0009987; cellular process | GO:0001973; adenosine receptor signaling pathway | 9.779E-06 | 7.170E-04 | ADORA1, ADORA2A, ADORA3 |
| MF | GO:0005488; binding | GO:0051721; protein phosphatase 2A binding | 1.070E-05 | 7.795E-04 | AKT1, MAPT, PTPN1, TP53 |
| BP | GO:0051179; localization | GO:0006909; phagocytosis | 1.201E-05 | 8.631E-04 | ADORA1, ADORA2A, ALOX15, AXL, ELANE |
| BP | GO:0009987; cellular process | GO:2001237; negative regulation of extrinsic apoptotic signaling pathway | 1.248E-05 | 8.911E-04 | AKT1, DAPK1, HTT, LMNA, MCL1, SRC |
| BP | GO:0009987; cellular process | GO:0070301; cellular response to hydrogen peroxide | 1.303E-05 | 9.227E-04 | AKR1B1, AXL, CDK1, CYP1B1, STAT6 |
| BP | GO:0009987; cellular process | GO:0071456; cellular response to hypoxia | 1.319E-05 | 9.297E-04 | AKT1, HIF1A, LMNA, OPRD1, SRC, TP53 |
| CC | GO:0043226; organelle | GO:0005654; nucleoplasm | 1.463E-05 | 1.018E-03 | ADK, AKR1B1, AKT1, ALOX5, AURKB, BLM, CAMK2B, CDK1, CSNK2A1, ESR1, ESR2, GSK3B, HIF1A, HPGD, HTT, LMNA, MAPK1, MCL1, NEK2, NEK6, NFKB1, NUAK1, PIM1, PKN1, POLB, RECQL, SMN1, SMN2, SRC, STAT6, TP53, VCP |
| BP | Unclassified; | GO:0044236; multicellular organism metabolic process | 1.471E-05 | 1.020E-03 | HIF1A, MMP13, MMP2, MMP3, MMP9, PLA2G1B |
| BP | GO:0009987; cellular process | GO:0071276; cellular response to cadmium ion | 1.626E-05 | 1.107E-03 | AKT1, CYP1A2, MAPK1, MMP9 |
| CC | GO:0044425; membrane part | GO:0005887; integral component of plasma membrane | 1.620E-05 | 1.107E-03 | ABCC1, ADORA1, ADORA2A, ADORA3, ALK, AXL, BACE1, DRD3, DRD4, FLT3, HTR2C, IGF1R, KDR, MET, NPSR1, OPRD1, SLC28A1, SLC28A2, SLC28A3, TSHR |
| MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 1.852E-05 | 1.241E-03 | CSNK2A1, HIF1A, KDR, MAPT |
| MF | GO:0005488; binding | GO:0034452; dynactin binding | 1.907E-05 | 1.266E-03 | GSK3B, HTT, MAPT |
| BP | GO:0032502; developmental process | GO:0007568; aging | 1.989E-05 | 1.313E-03 | AKT1, AURKB, CDK1, CYP1A1, MPO, NOX4, POLB, TP53 |
| BP | GO:0051179; localization | GO:0015860; purine nucleoside transmembrane transport | 2.444E-05 | 1.552E-03 | SLC28A2, SLC28A3 |
| BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 2.444E-05 | 1.552E-03 | ALOX12, ALOX15 |
| MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 2.444E-05 | 1.552E-03 | ESR1, ESR2 |
| MF | GO:0005215; transporter activity | GO:0015389; pyrimidine- and adenine-specific:sodium symporter activity | 2.444E-05 | 1.552E-03 | SLC28A1, SLC28A3 |
| MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 2.444E-05 | 1.552E-03 | ALOX12, ALOX15 |
| MF | GO:0005215; transporter activity | GO:0015211; purine nucleoside transmembrane transporter activity | 2.444E-05 | 1.552E-03 | SLC28A2, SLC28A3 |
| BP | GO:0050896; response to stimulus | GO:0045471; response to ethanol | 2.459E-05 | 1.557E-03 | CA3, CDK1, DRD3, HPGD, POLB, TP53 |
| BP | GO:0008283; cell proliferation | GO:0033598; mammary gland epithelial cell proliferation | 2.534E-05 | 1.594E-03 | ESR1, MAPK1, STAT6 |
| BP | GO:0009987; cellular process | GO:0048010; vascular endothelial growth factor receptor signaling pathway | 2.935E-05 | 1.811E-03 | AXL, KDR, PIK3R1, PTK2, SRC |
| BP | GO:0007610; behavior | GO:0007626; locomotory behavior | 3.107E-05 | 1.901E-03 | ADORA2A, ALK, DRD3, DRD4, GAA, HTR2C, OPRD1 |
| BP | Unclassified; | GO:0044243; multicellular organismal catabolic process | 3.139E-05 | 1.909E-03 | MMP13, MMP2, MMP3, MMP9, PLA2G1B |
| BP | GO:0023052; signaling | GO:0032230; positive regulation of synaptic transmission, GABAergic | 3.282E-05 | 1.991E-03 | ADORA2A, CA2, CA7 |
| CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 3.969E-05 | 2.368E-03 | ABCC1, ADORA1, CA2, CA4, CA9, HPGD, TSHR |
| BP | GO:0032502; developmental process | GO:0060065; uterus development | 4.162E-05 | 2.449E-03 | CYP19A1, ESR1, SRC |
| BP | GO:0009987; cellular process | GO:0032459; regulation of protein oligomerization | 4.565E-05 | 2.650E-03 | MMP3, OPRD1, SRC, TP53 |
| BP | GO:0009987; cellular process | GO:0022617; extracellular matrix disassembly | 4.601E-05 | 2.664E-03 | ELANE, MMP13, MMP2, MMP3, MMP9 |
| CC | GO:0044464; cell part | GO:0005739; mitochondrion | 5.903E-05 | 3.330E-03 | AKT1, CA5A, CA5B, CDK1, CYP1A1, CYP1B1, ESR2, GSK3B, HSD17B10, MAOA, MAPK1, MCL1, MMP2, MPO, NFKB1, NOX4, SRC, TP53 |
| BP | GO:0009987; cellular process | GO:2000811; negative regulation of anoikis | 6.357E-05 | 3.513E-03 | MCL1, PTK2, SRC |
| CC | GO:0044464; cell part | GO:0030673; axolemma | 6.357E-05 | 3.513E-03 | ADORA1, ADORA2A, MAPT |
| BP | Unclassified; | GO:0044259; multicellular organismal macromolecule metabolic process | 6.917E-05 | 3.775E-03 | HIF1A, MMP13, MMP2, MMP3, MMP9 |
| BP | GO:0050896; response to stimulus | GO:0032496; response to lipopolysaccharide | 7.205E-05 | 3.854E-03 | AXL, CYP1A1, CYP1A2, ELANE, HPGD, MPO, NFKB1, SRC |
| BP | GO:0009987; cellular process | GO:0090199; regulation of release of cytochrome c from mitochondria | 7.302E-05 | 3.854E-03 | AKT1, LMNA, MMP9, TP53 |
| BP | GO:0051179; localization | GO:1904823; purine nucleobase transmembrane transport | 7.310E-05 | 3.854E-03 | SLC28A1, SLC28A3 |
| BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 7.310E-05 | 3.854E-03 | CA2, CA7 |
| BP | GO:0051179; localization | GO:0015855; pyrimidine nucleobase transport | 7.310E-05 | 3.854E-03 | SLC28A1, SLC28A3 |
| MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 7.310E-05 | 3.854E-03 | CYP1A1, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 7.310E-05 | 3.854E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 7.310E-05 | 3.854E-03 | ALOX12, ALOX15 |
| CC | GO:0044464; cell part | GO:0099056; integral component of presynaptic membrane | 7.310E-05 | 3.854E-03 | ADORA1, ADORA2A |
| CC | GO:0044464; cell part | GO:0005829; cytosol | 7.361E-05 | 3.862E-03 | ADK, AKR1B1, AKT1, ALOX12, ALOX15, ALOX5, AURKB, BLM, CA1, CA2, CA3, CA7, CAMK2B, CDK1, CSNK2A1, FLT3, GLO1, GSK3B, HIF1A, HPGD, HTT, LMNA, MAPK1, MAPT, MCL1, NEK2, NEK6, NFKB1, PIK3R1, PIM1, PKN1, PLA2G1B, PTK2, PTPN1, PYGL, SMN1, SMN2, SRC, STAT6, TP53, VCP, XDH |
| BP | GO:0065007; biological regulation | GO:1904355; positive regulation of telomere capping | 7.691E-05 | 3.997E-03 | AURKB, MAPK1, NEK2 |
| MF | GO:0003824; catalytic activity | GO:0035173; histone kinase activity | 7.691E-05 | 3.997E-03 | AURKB, CDK1, PKN1 |
| BP | GO:0032502; developmental process | GO:0009653; anatomical structure morphogenesis | 8.087E-05 | 4.193E-03 | ADORA2A, AXL, CA2, CA9, CYP1B1, ESR1, GAA, HIF1A, HPGD, MAPK1, MET, MMP13, MMP2, NOX4, POLB, PTK2, SRC, STAT6 |
| BP | GO:0048511; rhythmic process | GO:0048511; rhythmic process | 8.573E-05 | 4.406E-03 | AXL, CSNK2A1, DRD3, DRD4, ESR1, GSK3B, SRC, TP53 |
| BP | GO:0008152; metabolic process | GO:2000379; positive regulation of reactive oxygen species metabolic process | 8.594E-05 | 4.406E-03 | AKT1, MAPT, NOX4, TP53, XDH |
| BP | GO:0008152; metabolic process | GO:0038083; peptidyl-tyrosine autophosphorylation | 8.675E-05 | 4.413E-03 | IGF1R, KDR, PTK2, SRC |
| BP | GO:0032501; multicellular organismal process | GO:0045187; regulation of circadian sleep/wake cycle, sleep | 1.088E-04 | 5.422E-03 | ADORA1, ADORA2A, DRD3 |
| BP | GO:0009987; cellular process | GO:0051897; positive regulation of protein kinase B signaling | 1.113E-04 | 5.534E-03 | AXL, MET, NOX4, PIK3R1, PTK2, SRC |
| BP | GO:0051179; localization | GO:0051924; regulation of calcium ion transport | 1.349E-04 | 6.526E-03 | ADORA2A, CAMK2B, DRD4, HTT, NPSR1, OPRD1, PLA2G1B |
| MF | Unclassified; | GO:0099600; transmembrane receptor activity | 1.374E-04 | 6.617E-03 | ADORA1, ADORA2A, ADORA3, ALK, AXL, CXCR1, DRD3, DRD4, FLT3, HPGD, HTR2C, IGF1R, KDR, MET, NPSR1, OPRD1, TSHR |
| BP | GO:0002376; immune system process | GO:0043312; neutrophil degranulation | 1.413E-04 | 6.777E-03 | ALOX5, CXCR1, ELANE, GAA, MAPK1, MMP9, MPO, NFKB1, PYGL, VCP |
| MF | GO:0005488; binding | GO:0046983; protein dimerization activity | 1.441E-04 | 6.866E-03 | ABCG2, ADORA1, ADORA2A, AKT1, AXL, BLM, CAMK2B, FLT3, HIF1A, HPGD, MAPT, MCL1, NFKB1, PIK3R1, PYGL, TP53, XDH |
| BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 1.457E-04 | 6.868E-03 | CYP1A1, CYP1A2 |
| MF | GO:0005488; binding | GO:0034056; estrogen response element binding | 1.457E-04 | 6.868E-03 | ESR1, ESR2 |
| BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 1.483E-04 | 6.913E-03 | CYP1A1, POLB, TP53 |
| BP | GO:0008152; metabolic process | GO:0005977; glycogen metabolic process | 1.498E-04 | 6.937E-03 | AKT1, GAA, GSK3B, PYGL |
| BP | GO:0009987; cellular process | GO:0000226; microtubule cytoskeleton organization | 1.534E-04 | 7.062E-03 | AURKB, CDK1, HTT, LMNA, MAPT, NEK2, NEK6, PTK2 |
| BP | GO:0008152; metabolic process | GO:0045862; positive regulation of proteolysis | 1.543E-04 | 7.089E-03 | AKT1, CDK1, DAPK1, GSK3B, MAPT, PTK2, SRC, VCP, XDH |
| BP | GO:0022610; biological adhesion | GO:0001952; regulation of cell-matrix adhesion | 1.627E-04 | 7.396E-03 | GSK3B, KDR, PIK3R1, PTK2, SRC |
| BP | GO:0008283; cell proliferation | GO:1904707; positive regulation of vascular smooth muscle cell proliferation | 1.711E-04 | 7.664E-03 | HPGD, MMP2, MMP9 |
| BP | GO:0009987; cellular process | GO:0030520; intracellular estrogen receptor signaling pathway | 1.711E-04 | 7.664E-03 | ESR1, ESR2, SRC |
| BP | GO:0051179; localization | GO:0043270; positive regulation of ion transport | 1.855E-04 | 8.236E-03 | ADORA1, ADORA2A, AKT1, DRD4, HTT, NPSR1, PLA2G1B |
| BP | GO:0002376; immune system process | GO:0048534; hematopoietic or lymphoid organ development | 1.861E-04 | 8.238E-03 | FLT3, HIF1A, KDR, MAPK1, PKN1, POLB |
| BP | GO:0051179; localization | GO:0050482; arachidonic acid secretion | 1.960E-04 | 8.502E-03 | DRD3, DRD4, PLA2G1B |
| BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 1.960E-04 | 8.502E-03 | CYP1A1, CYP1A2, CYP1B1 |
| BP | GO:0009987; cellular process | GO:0010822; positive regulation of mitochondrion organization | 1.986E-04 | 8.562E-03 | GSK3B, HIF1A, HTT, KDR, MMP9, TP53 |
| MF | Unclassified; | GO:0004872; receptor activity | 2.028E-04 | 8.708E-03 | ADORA1, ADORA2A, ADORA3, ALK, AXL, CXCR1, DRD3, DRD4, ESR1, ESR2, FLT3, HPGD, HTR2C, IGF1R, KDR, MET, NPSR1, OPRD1, TSHR |
| MF | GO:0003824; catalytic activity | GO:0009055; electron transfer activity | 2.032E-04 | 8.708E-03 | AKR1B1, CYP19A1, CYP1A2, NOX4, XDH |
| BP | GO:0065007; biological regulation | GO:0051091; positive regulation of DNA binding transcription factor activity | 2.107E-04 | 9.012E-03 | AKT1, ALK, ESR1, ESR2, NFKB1, OPRD1, PLA2G1B |
| BP | GO:0009987; cellular process | GO:0030168; platelet activation | 2.213E-04 | 9.335E-03 | AKT1, AXL, MAPK1, PIK3R1, SRC |
| BP | GO:0008152; metabolic process | GO:0051122; hepoxilin biosynthetic process | 2.421E-04 | 9.946E-03 | ALOX12, ALOX15 |
| MF | GO:0003824; catalytic activity | GO:0009378; four-way junction helicase activity | 2.421E-04 | 9.946E-03 | BLM, RECQL |
| MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 3.395E-23 | 7.392E-19 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 1.696E-16 | 3.694E-13 | CA1, CA12, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
| BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.298E-15 | 1.570E-12 | CA1, CA12, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 2.084E-22 | 4.001E-20 | CA12; CA1; CA3; CA5B; CA2; CA5A; CA4; CA7; CA6; CA9; CA14 |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 9.047E-13 | 8.685E-11 | CAMK2B; SRC; MMP2; PIK3R1; HIF1A; ESR1; MMP9; PTK2; IGF1R; KDR; AKT1; MAPK1; TP53; MET |
| hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 1.948E-09 | 9.349E-08 | GSK3B; SRC; AKT1; MAPK1; PIK3R1; ESR1; NFKB1; ESR2 |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 6.415E-09 | 1.759E-07 | GSK3B; FLT3; DAPK1; MMP2; PIK3R1; HIF1A; MMP9; NFKB1; PTK2; IGF1R; AKT1; MAPK1; MET; TP53 |
| hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 1.049E-09 | 6.714E-08 | HPGD; FLT3; MMP3; TP53; MPO; MMP9; MET; ELANE; NFKB1; PTK2; IGF1R |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 6.226E-09 | 1.759E-07 | OPRD1; ABCC1; ADORA3; ADORA1; AKT1; MAPK1; PIK3R1; TP53; NFKB1 |
| hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 2.506E-08 | 6.015E-07 | SRC; MMP2; AKT1; MAPK1; PIK3R1; ESR1; MMP9; ESR2 |
| hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 8.618E-08 | 1.379E-06 | GSK3B; KDR; AKT1; MAPK1; PIK3R1; PKN1; TP53; MET; PTK2; NFKB1; IGF1R; MCL1 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 4.536E-09 | 1.742E-07 | CYP2C9; CYP2C8; PLA2G1B; CYP1A2; ALOX15; CYP3A4 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 3.233E-08 | 6.897E-07 | FLT3; AKT1; MAPK1; PIK3R1; TP53; MET; HIF1A |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 6.615E-08 | 1.155E-06 | CYP2C9; CYP2C8; MAOA; ALOX5; ALOX15; HTR2C; MAPK1; ALOX12 |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 9.941E-08 | 1.468E-06 | GSK3B; SRC; AKT1; MAPK1; PIK3R1; TP53; ESR1; HIF1A |
| hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 4.099E-08 | 7.871E-07 | DAPK1; SRC; MMP2; MAPK1; MMP9; TP53 |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 2.351E-07 | 2.821E-06 | GSK3B; AKT1; MAPK1; PIK3R1; TP53; NFKB1; IGF1R |
| hsa04012 | ErbB signaling pathway_Homo sapiens_hsa04012 | 2.010E-07 | 2.572E-06 | CAMK2B; GSK3B; SRC; AKT1; MAPK1; PIK3R1; PTK2 |
| hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 1.399E-07 | 1.919E-06 | ALOX5; HSD17B2; CYP1A1; CYP1B1; CYP19A1; IGF1R |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 5.130E-07 | 4.725E-06 | SRC; AKT1; MAPK1; STAT6; PIK3R1; TP53; MMP9; NFKB1 |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 3.110E-07 | 3.513E-06 | FLT3; PIM1; AKT1; MAPK1; PIK3R1; NFKB1 |
| hsa04510 | Focal adhesion_Homo sapiens_hsa04510 | 5.558E-07 | 4.850E-06 | GSK3B; SRC; KDR; AKT1; MAPK1; PIK3R1; MET; PTK2; IGF1R |
| hsa04370 | VEGF signaling pathway_Homo sapiens_hsa04370 | 4.686E-07 | 4.725E-06 | SRC; KDR; AKT1; MAPK1; PIK3R1; PTK2 |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 6.402E-07 | 5.344E-06 | CAMK2B; AKT1; MAPK1; PIK3R1; HIF1A; NFKB1; IGF1R |
| hsa05214 | Glioma_Homo sapiens_hsa05214 | 6.865E-07 | 5.492E-06 | CAMK2B; AKT1; MAPK1; PIK3R1; TP53; IGF1R |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 5.168E-07 | 4.725E-06 | CYP2C9; CYP2C8; PLA2G1B; ALOX5; ALOX15; ALOX12 |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 3.456E-07 | 3.686E-06 | CYP1A2; HSD17B2; CYP1A1; CYP1B1; CYP3A4; CYP19A1 |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 1.799E-06 | 1.279E-05 | CAMK2B; GSK3B; AKT1; MAPK1; PIK3R1; TP53; NFKB1 |
| hsa05218 | Melanoma_Homo sapiens_hsa05218 | 1.163E-06 | 8.932E-06 | AKT1; MAPK1; PIK3R1; TP53; MET; IGF1R |
| hsa04062 | Chemokine signaling pathway_Homo sapiens_hsa04062 | 3.305E-06 | 2.188E-05 | GSK3B; CXCR1; SRC; AKT1; MAPK1; PIK3R1; NFKB1; PTK2 |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 5.024E-06 | 3.112E-05 | LMNA; AKT1; MAPK1; PIK3R1; TP53; NFKB1; MCL1 |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 5.234E-06 | 3.141E-05 | CAMK2B; ADORA2A; ADORA1; AKT1; MAPK1; PIK3R1; NFKB1; TSHR |
| hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 1.487E-06 | 1.098E-05 | PTPN1; CSNK2A1; SRC; MAPK1; MET; IGF1R |
| hsa04015 | Rap1 signaling pathway_Homo sapiens_hsa04015 | 8.044E-06 | 4.542E-05 | ADORA2A; SRC; KDR; AKT1; MAPK1; PIK3R1; MET; IGF1R |
| hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 9.168E-06 | 5.029E-05 | MMP2; PIM1; AKT1; MAPK1; PIK3R1; NFKB1 |
| hsa04014 | Ras signaling pathway_Homo sapiens_hsa04014 | 1.369E-05 | 6.917E-05 | PLA2G1B; KDR; AKT1; MAPK1; PIK3R1; MET; NFKB1; IGF1R |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 1.303E-05 | 6.761E-05 | ABCC1; PIM1; CYP1B1; MAPK1; TP53; MMP9; MET; NFKB1; MCL1 |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 2.725E-06 | 1.869E-05 | CYP2C9; CYP2C8; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 2.160E-05 | 9.214E-05 | PLA2G1B; MAOA; GAA; ALOX15; ADK; AKR1B1; ALOX12; PYGL; CYP3A4; CYP19A1; HSD17B10; CYP2C9; CYP2C8; ALOX5; HSD17B2; CYP1A2; CYP1A1; XDH |
| hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 1.497E-05 | 7.065E-05 | MMP3; AKT1; MAPK1; PIK3R1; MMP9; NFKB1 |
| hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 1.420E-05 | 6.993E-05 | PTPN1; GSK3B; AKT1; PIK3R1; PYGL; NFKB1 |
| hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 4.987E-06 | 3.112E-05 | GSK3B; AKT1; MAPK1; PIK3R1; TP53 |
| hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 7.219E-06 | 4.200E-05 | ALK; AKT1; MAPK1; PIK3R1; TP53 |
| hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 1.195E-05 | 6.376E-05 | GSK3B; AKT1; MAPK1; PIK3R1; TP53 |
| hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 5.389E-05 | 1.952E-04 | GSK3B; CSNK2A1; CDK1; AKT1; PIK3R1; TP53; NFKB1 |
| hsa04728 | Dopaminergic synapse_Homo sapiens_hsa04728 | 3.695E-05 | 1.448E-04 | CAMK2B; GSK3B; MAOA; AKT1; DRD3; DRD4 |
| hsa04080 | Neuroactive ligand-receptor interaction_Homo sapiens_hsa04080 | 5.662E-05 | 1.976E-04 | OPRD1; ADORA2A; ADORA3; ADORA1; HTR2C; DRD3; DRD4; TSHR |
| hsa05162 | Measles_Homo sapiens_hsa05162 | 4.969E-05 | 1.835E-04 | GSK3B; CSNK2A1; AKT1; PIK3R1; TP53; NFKB1 |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 4.385E-05 | 1.651E-04 | GSK3B; AKT1; MAPK1; PIK3R1; TP53; NFKB1 |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 5.914E-05 | 1.992E-04 | POLB; SRC; CDK1; MAPK1; PIK3R1; TP53; NFKB1 |
| hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 2.662E-05 | 1.065E-04 | GSK3B; AKT1; MAPK1; PIK3R1; NFKB1 |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 1.626E-05 | 7.261E-05 | AKT1; MAPK1; PIK3R1; TP53; NFKB1 |
| hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 1.626E-05 | 7.261E-05 | AKT1; MAPK1; PIK3R1; MET; HIF1A |
| hsa04910 | Insulin signaling pathway_Homo sapiens_hsa04910 | 5.612E-05 | 1.976E-04 | PTPN1; GSK3B; AKT1; MAPK1; PIK3R1; PYGL |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 2.662E-05 | 1.065E-04 | AKT1; MAPK1; PIK3R1; TP53; NFKB1 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 1.509E-05 | 7.065E-05 | CYP2C9; CYP2C8; CYP1A2; CYP1A1; CYP3A4 |
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 2.022E-05 | 8.823E-05 | CYP2C9; CYP2C8; MAOA; CYP1A2; CYP3A4 |
| hsa04022 | cGMP-PKG signaling pathway_Homo sapiens_hsa04022 | 1.544E-04 | 4.706E-04 | OPRD1; ADORA3; ADORA1; AKT1; MAPK1; PIK3R1 |
| hsa04750 | Inflammatory mediator regulation of TRP channels_Homo sapiens_hsa04750 | 1.095E-04 | 3.504E-04 | CAMK2B; SRC; HTR2C; ALOX12; PIK3R1 |
| hsa04914 | Progesterone-mediated oocyte maturation_Homo sapiens_hsa04914 | 1.095E-04 | 3.504E-04 | CDK1; AKT1; MAPK1; PIK3R1; IGF1R |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 2.662E-05 | 1.065E-04 | CYP2C9; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
| hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 8.985E-05 | 2.974E-04 | AKT1; PIK3R1; TP53; NFKB1; IGF1R |
| hsa04660 | T cell receptor signaling pathway_Homo sapiens_hsa04660 | 1.450E-04 | 4.563E-04 | GSK3B; AKT1; MAPK1; PIK3R1; NFKB1 |
| hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 5.876E-05 | 1.992E-04 | AKT1; PIK3R1; TP53; NFKB1; PTK2 |
| hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 2.616E-04 | 7.611E-04 | ALOX5; AKT1; MAPK1; PIK3R1; NFKB1 |
| hsa04550 | Signaling pathways regulating pluripotency of stem cells_Homo sapiens_hsa04550 | 6.121E-04 | 1.703E-03 | GSK3B; AKT1; MAPK1; PIK3R1; IGF1R |
| hsa04630 | Jak-STAT signaling pathway_Homo sapiens_hsa04630 | 9.901E-04 | 2.640E-03 | PIM1; AKT1; STAT6; PIK3R1; MCL1 |
| hsa05166 | HTLV-I infection_Homo sapiens_hsa05166 | 1.530E-03 | 3.917E-03 | POLB; GSK3B; AKT1; PIK3R1; TP53; NFKB1 |
| hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 1.301E-03 | 3.422E-03 | BACE1; GSK3B; MAPK1; MAPT; HSD17B10 |
| hsa05164 | Influenza A_Homo sapiens_hsa05164 | 1.558E-03 | 3.936E-03 | GSK3B; AKT1; MAPK1; PIK3R1; NFKB1 |
| hsa05152 | Tuberculosis_Homo sapiens_hsa05152 | 1.679E-03 | 4.133E-03 | CAMK2B; SRC; AKT1; MAPK1; NFKB1 |
| hsa04912 | GnRH signaling pathway_Homo sapiens_hsa04912 | 9.681E-04 | 2.618E-03 | CAMK2B; SRC; MMP2; MAPK1 |
| hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 1.426E-03 | 3.700E-03 | AKT1; MAPK1; PIK3R1; HIF1A |
| hsa04725 | Cholinergic synapse_Homo sapiens_hsa04725 | 2.017E-03 | 4.841E-03 | CAMK2B; AKT1; MAPK1; PIK3R1 |
| hsa04611 | Platelet activation_Homo sapiens_hsa04611 | 2.842E-03 | 6.654E-03 | SRC; AKT1; MAPK1; PIK3R1 |
| hsa04620 | Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | 1.704E-03 | 4.141E-03 | AKT1; MAPK1; PIK3R1; NFKB1 |
| hsa05142 | Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | 1.588E-03 | 3.961E-03 | AKT1; MAPK1; PIK3R1; NFKB1 |
| hsa04114 | Oocyte meiosis_Homo sapiens_hsa04114 | 2.927E-03 | 6.770E-03 | CAMK2B; CDK1; MAPK1; IGF1R |
| hsa04540 | Gap junction_Homo sapiens_hsa04540 | 8.540E-04 | 2.342E-03 | SRC; CDK1; HTR2C; MAPK1 |
| hsa04380 | Osteoclast differentiation_Homo sapiens_hsa04380 | 3.770E-03 | 8.330E-03 | AKT1; MAPK1; PIK3R1; NFKB1 |
| hsa04670 | Leukocyte transendothelial migration_Homo sapiens_hsa04670 | 2.519E-03 | 5.972E-03 | MMP2; PIK3R1; MMP9; PTK2 |
| hsa04360 | Axon guidance_Homo sapiens_hsa04360 | 3.284E-03 | 7.505E-03 | GSK3B; MAPK1; MET; PTK2 |
| hsa04144 | Endocytosis_Homo sapiens_hsa04144 | 8.236E-03 | 1.597E-02 | CXCR1; SRC; KDR; MET; IGF1R |
| hsa04068 | FoxO signaling pathway_Homo sapiens_hsa04068 | 3.873E-03 | 8.450E-03 | AKT1; MAPK1; PIK3R1; IGF1R |
| hsa04310 | Wnt signaling pathway_Homo sapiens_hsa04310 | 4.885E-03 | 1.031E-02 | CAMK2B; GSK3B; CSNK2A1; TP53 |
| hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 7.729E-03 | 1.530E-02 | AKT1; MAPK1; MAPT; TP53; NFKB1 |
| hsa04072 | Phospholipase D signaling pathway_Homo sapiens_hsa04072 | 5.132E-03 | 1.071E-02 | CXCR1; AKT1; MAPK1; PIK3R1 |
| hsa05100 | Bacterial invasion of epithelial cells_Homo sapiens_hsa05100 | 5.418E-04 | 1.530E-03 | SRC; PIK3R1; MET; PTK2 |
| hsa04932 | Non-alcoholic fatty liver disease (NAFLD)_Homo sapiens_hsa04932 | 6.061E-03 | 1.225E-02 | GSK3B; AKT1; PIK3R1; NFKB1 |
| hsa04261 | Adrenergic signaling in cardiomyocytes_Homo sapiens_hsa04261 | 5.650E-03 | 1.154E-02 | CAMK2B; AKT1; MAPK1; PIK3R1 |
| hsa04921 | Oxytocin signaling pathway_Homo sapiens_hsa04921 | 7.097E-03 | 1.419E-02 | CAMK2B; SRC; MAPK1; PIK3R1 |
| hsa05168 | Herpes simplex infection_Homo sapiens_hsa05168 | 1.217E-02 | 2.265E-02 | CSNK2A1; CDK1; TP53; NFKB1 |
| hsa04810 | Regulation of actin cytoskeleton_Homo sapiens_hsa04810 | 1.972E-02 | 3.446E-02 | SRC; MAPK1; PIK3R1; PTK2 |
| hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 1.978E-04 | 5.935E-04 | AKT1; MAPK1; PIK3R1; HIF1A |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 1.512E-04 | 4.683E-04 | ADORA1; AKT1; PIK3R1; TSHR |
| hsa04530 | Tight junction_Homo sapiens_hsa04530 | 2.938E-02 | 4.740E-02 | CSNK2A1; SRC; AKT1 |
| hsa05120 | Epithelial cell signaling in Helicobacter pylori infection_Homo sapiens_hsa05120 | 3.209E-04 | 9.195E-04 | CXCR1; SRC; MET; NFKB1 |
| hsa04152 | AMPK signaling pathway_Homo sapiens_hsa04152 | 2.189E-02 | 3.687E-02 | AKT1; PIK3R1; IGF1R |
| hsa04110 | Cell cycle_Homo sapiens_hsa04110 | 2.189E-02 | 3.687E-02 | GSK3B; CDK1; TP53 |
| hsa04270 | Vascular smooth muscle contraction_Homo sapiens_hsa04270 | 2.010E-02 | 3.476E-02 | ADORA2A; PLA2G1B; MAPK1 |
| hsa04916 | Melanogenesis_Homo sapiens_hsa04916 | 1.239E-02 | 2.265E-02 | CAMK2B; GSK3B; MAPK1 |
| hsa04922 | Glucagon signaling pathway_Homo sapiens_hsa04922 | 1.272E-02 | 2.305E-02 | CAMK2B; AKT1; PYGL |
| hsa05146 | Amoebiasis_Homo sapiens_hsa05146 | 1.239E-02 | 2.265E-02 | PIK3R1; NFKB1; PTK2 |
| hsa04666 | Fc gamma R-mediated phagocytosis_Homo sapiens_hsa04666 | 1.018E-02 | 1.917E-02 | AKT1; MAPK1; PIK3R1 |
| hsa05132 | Salmonella infection_Homo sapiens_hsa05132 | 8.227E-03 | 1.597E-02 | MAPK1; PKN1; NFKB1 |
| hsa04664 | Fc epsilon RI signaling pathway_Homo sapiens_hsa04664 | 4.286E-03 | 9.246E-03 | AKT1; MAPK1; PIK3R1 |
| hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 4.838E-03 | 1.031E-02 | CA2; CYP3A4; ABCG2 |
| hsa04213 | Longevity regulating pathway - multiple species_Homo sapiens_hsa04213 | 3.613E-03 | 8.161E-03 | AKT1; PIK3R1; IGF1R |
| hsa05131 | Shigellosis_Homo sapiens_hsa05131 | 3.775E-03 | 8.330E-03 | SRC; MAPK1; NFKB1 |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 3.990E-05 | 1.532E-04 | MAOA; CYP1A2; CYP1A1; CYP1B1 |
| hsa04621 | NOD-like receptor signaling pathway_Homo sapiens_hsa04621 | 3.067E-02 | 4.867E-02 | MAPK1; NFKB1 |
| hsa05134 | Legionellosis_Homo sapiens_hsa05134 | 2.872E-02 | 4.672E-02 | VCP; NFKB1 |
| hsa05217 | Basal cell carcinoma_Homo sapiens_hsa05217 | 2.872E-02 | 4.672E-02 | GSK3B; TP53 |
| hsa00500 | Starch and sucrose metabolism_Homo sapiens_hsa00500 | 2.969E-02 | 4.750E-02 | GAA; PYGL |
| hsa05030 | Cocaine addiction_Homo sapiens_hsa05030 | 2.316E-02 | 3.834E-02 | MAOA; NFKB1 |
| hsa04930 | Type II diabetes mellitus_Homo sapiens_hsa04930 | 2.229E-02 | 3.721E-02 | MAPK1; PIK3R1 |
| hsa04973 | Carbohydrate digestion and absorption_Homo sapiens_hsa04973 | 1.974E-02 | 3.446E-02 | AKT1; PIK3R1 |
| hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 2.058E-02 | 3.528E-02 | CYP3A4; XDH |
| hsa02010 | ABC transporters_Homo sapiens_hsa02010 | 1.892E-02 | 3.364E-02 | ABCC1; ABCG2 |
| hsa04960 | Aldosterone-regulated sodium reabsorption_Homo sapiens_hsa04960 | 1.505E-02 | 2.701E-02 | MAPK1; PIK3R1 |
| hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 9.088E-03 | 1.728E-02 | GAA; AKR1B1 |
| hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 8.508E-03 | 1.634E-02 | MAPK1; TP53 |
| hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 5.402E-03 | 1.115E-02 | CA2; CA4 |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 2.259E-04 | 6.672E-04 | CYP1A2; XDH |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| C00-D49: Neoplasms | Glioma | C71 | KDR |
| C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
| C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
| C00-D49: Neoplasms | Glioblastoma multiforme | C71 | SRC |
| NA: NA | GIST | NA | FLT3 |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1; CA1; CA1; ADORA3; ADORA2A; ADORA1 |
| A00-B99: Certain infectious and parasitic diseases | Septic shock | A41.9 | ELANE |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | HTR2C; DRD3; DRD4 |
| A00-B99: Certain infectious and parasitic diseases | Sepsis | A40, A41 | ADORA1 |
| NA: NA | Gonorrheal vaginitis | NA | ESR1 |
| I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR |
| C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET |
| C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR |
| C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | FLT3; IGF1R; MMP9; TP53; KDR |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cough | R05 | OPRD1 |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | AKR1B1; TP53; KDR; KDR |
| I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | ADORA1; XDH |
| L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | MMP2; ESR1 |
| N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1 |
| N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
| N00-N99: Diseases of the genitourinary system | Renal failure | N17, N18, N19 | ADORA1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R |
| H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | ALOX5; MMP13; MMP3; MMP2 |
| I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CAMK2B; MAOA; OPRD1; HTR2C; CYP3A4 |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; CA2 |
| I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
| C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | IGF1R; ESR1; ESR1 |
| C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | ESR1 |
| I00-I99: Diseases of the circulatory system | Coronary disorder diagnosis | I20-I25 | ADORA2A |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Fatigue | R53 | ADORA1 |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR; KDR |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | ALOX5 |
| J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | MAOA; OPRD1; HTR2C |
| C00-D49: Neoplasms | Melanoma | C43 | KDR; KDR |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | ADORA3 |
| NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
| NA: NA | Hepatitis C virus infection | NA | ADORA3 |
| C00-D49: Neoplasms | Hematologic malignancies | C81-C86 | AKT1 |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | SRC; AURKB; TP53 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
| NA: NA | Postmenopausal disorder | NA | ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Premature ejaculation | F52.4 | OPRD1 |
| C00-D49: Neoplasms | AML | NA | FLT3; KDR |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; ADORA3; KDR |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9 |
| C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; ABCC1; ABCC1; XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ADORA1; ESR1 |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADORA2A; ADORA1 |
| J00-J99: Diseases of the respiratory system | Bronchiectasis | J47, Q33.4 | ELANE |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Convulsions | R56.0 | ADK |
| H00-H59: Diseases of the eye and adnexa | Corneal ulcers | H16.0 | MMP3 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
| C00-D49: Neoplasms | Aggressive non-hodgkin's lymphoma | C81, C81-C86, C82-C85, C91-C95 | HTR2C |
| C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR |
| NA: NA | Acute respiratory distress syndrome | NA | ELANE; ELANE; ELANE |
| C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1 |
| C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1; SRC |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of corticosteroid responsive dermatoses | L20-L30 | PLA2G1B |
| K00-K95: Diseases of the digestive system | Gastric motility disorder | K22.4 | DRD3 |
| C00-D49: Neoplasms | Gastric cancer | C16 | KDR; KDR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1; DRD3 |
| N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET |
| A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3 |
| Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1 |
| A00-B99: Certain infectious and parasitic diseases | HCV infection | B17.1, B18.2 | MMP3 |
| NA: NA | Colour dead tissues | NA | PTPN1 |
| C00-D49: Neoplasms | Colon cancer | C50 | FLT3 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Contact dermatitis | L23, L24, L25 | PLA2G1B |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9; KDR |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Moderate-to-severe pain | R52, G89 | OPRD1 |
| C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; KDR |
| C00-D49: Neoplasms | Advanced prostate cancer | C61 | ESR1 |
| C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Erectile dysfunction | F52.2, N48.4 | DRD4 |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA; ADK |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ADK |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | MPO; ADORA1; ESR1; ESR1 |
| A00-B99: Certain infectious and parasitic diseases | Infections | A00-B99 | PTPN1 |
| A00-B99: Certain infectious and parasitic diseases | Infections disease | A00-B99 | MPO |
| N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1 |
| I00-I99: Diseases of the circulatory system | Myocardial infarction | I21, I22 | ELANE; MMP3 |
| G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R |
| J00-J99: Diseases of the respiratory system | Mucolytic | J00-J99 | ELANE |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ALOX5; ADORA3 |
| G00-G99: Diseases of the nervous system G00-G99 | Acute migraine | G43 | OPRD1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Male sexual disorders | F52 | DRD3 |
| NA: NA | Acute nonspecific diarrhea | NA | OPRD1 |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | FLT3; FLT3; AURKB; TP53; TP53 |
| N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | ESR1 |
| K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA1; CA2 |
| I00-I99: Diseases of the circulatory system | Acute and chronic heart failure | I50 | ADORA1 |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | AKT1; CA9; HIF1A |
| A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5 |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
| N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1 |
| G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Emesis | R11 | DRD3 |
| I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
| NA: NA | Edema | NA | CA2 |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; IGF1R; IGF1R; AXL; KDR |
| C00-D49: Neoplasms | Non-small-cell lung cancer | NA | MMP2; KDR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PTPN1; HTR2C; HTR2C |
| L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | ADORA2A |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | HTR2C |
| C00-D49: Neoplasms | Metastasis | C00-C97 | AXL |
| N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAOA; MAPT; GSK3B |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | PLA2G1B; ADORA2A |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | MAOA; ADORA2A; ADORA1 |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | HTR2C; NPSR1; ESR1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | HTR2C; DRD3 |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| K00-K95: Diseases of the digestive system | Diarrhea-predominant IBS | K58.0 | OPRD1 |
| C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET |
| C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1 |
| J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | ALOX5 |
| H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1 |
| NA: NA | Myocardial ischaemia-reperfusion injury | NA | ELANE |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Myocardial reperfusion injury | T86.4 | AKT1 |
| C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Cystic fibrosis | E84 | ELANE; ELANE |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT; ADORA1 |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
| C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | MAOA; HTR2C |
| L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ALOX5 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | AKR1B1; PTPN1; HTR2C; GSK3B; ADORA1 |
| C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | SRC |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | MPO; ALOX5; ELANE; ELANE; ADORA2A |
| J00-J99: Diseases of the respiratory system | Acute lung injury | J80 | ELANE; ELANE; ELANE |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypertriglyceridemia | E78.1, E78.2, E78.3, I47-I49 | ADORA1 |
| C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3 |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Radionuclide imaging | W88 | ADORA2A |
| N00-N99: Diseases of the genitourinary system | Urinary incontinence | N39.3, N39.4, R32 | OPRD1 |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MPO; PLA2G1B; ALOX5; MMP13; ELANE |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp | L20-L30 | PLA2G1B |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | MPO; MAOA; ADORA2A; ADORA1 |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | MMP13; OPRD1; HTR2C; ADK; IGF1R; ADORA2A; CDK1; ESR1 |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | AKT1; FLT3; MMP2; KDR |
| C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3 |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR |
| NA: NA | Chronic diarrhea associated with inflammatory bowel disease | NA | OPRD1 |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | CA1 |
| N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1 |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2; KDR; KDR |
| NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PTPN1; PTPN1; NFKB1 |
| A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1 |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1 |
| I00-I99: Diseases of the circulatory system | Ischemic heart diseases | I20-I25 | OPRD1 |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | SRC; ADORA3 |
| I00-I99: Diseases of the circulatory system | Ischemic stroke | I61-I63 | MMP3 |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | PLA2G1B; ADORA2A |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | PLA2G1B; ALOX5; ALOX5; ELANE; ADORA2A; ADORA1 |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | ALOX5 |
| C00-D49: Neoplasms | Ovarian cancer | C56 | MMP2; KDR; KDR; KDR; KDR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | SRC; ESR1 |
| C00-D49: Neoplasms | Osteosarcoma | C40-C41 | SRC; GSK3B |
| C00-D49: Neoplasms | Overactive bladder disorder | C67, N32.81 | OPRD1 |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT |
| Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | ESR1 |
| C00-D49: Neoplasms | Prostate cancer | C61 | FLT3; ESR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | PLA2G1B; ALOX5 |
| NA: NA | Primary insomnia | NA | HTR2C |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | ALOX5; FLT3 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA |
| A00-B99: Certain infectious and parasitic diseases | Visceral leishmaniasis | B55.0 | PLA2G1B |
| C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | PTK2; TP53 |
| A00-B99: Certain infectious and parasitic diseases | Leishmaniasis | B55.0 | PLA2G1B |
| C00-D49: Neoplasms | Leukemia | C90-C95 | AKT1; FLT3; ESR1 |
| N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | ALOX5 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Atrial fibrillation | E78, I48 | ADORA1; ADORA1 |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
| Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1 |
| I00-I99: Diseases of the circulatory system | Orthostatic hypotension | I95.1 | ADORA1 |
| Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Nerve injury | T14.4 | PLA2G1B |
| I00-I99: Diseases of the circulatory system | Cardiac arrhythmias | I47-I49 | ADORA1; ADORA1 |
| I00-I99: Diseases of the circulatory system | Cardiac disease | I00-I99 | ADORA1 |
| I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR |
| J00-J99: Diseases of the respiratory system | Pulmonary disease | J00-J99 | ELANE |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | HTR2C; DRD3; DRD4 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R |
| J00-J99: Diseases of the respiratory system | Pulmonary emphysema | J43 | ELANE |
| C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2 |
| K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; CA4 |
| K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA; HTR2C |
| C00-D49: Neoplasms | Multiple myeloma | C90 | VCP; SRC; IGF1R |
| C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1 |
| C00-D49: Neoplasms | Cancer | C00-C96 | AKT1; MET; MCL1; CSNK2A1; CA1; FLT3; FLT3; CA9; MMP2; SRC; IGF1R; PTK2; GSK3B; ADORA3; HIF1A; CDK1; MAPK1; MMP9; NFKB1; PIM1; TP53; ESR1; ESR1; KDR |
| NA: NA | Sleep initiation and maintenance disorders | NA | HTR2C |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | PLA2G1B; ALOX5; ADORA1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cocaine addiction | F14.2 | DRD3 |
| C00-D49: Neoplasms | CLL | NA | FLT3 |
| C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | MAOA; MAOA; OPRD1; HTR2C; HTR2C |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | ADORA3 |
| N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; ESR1 |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine headaches | G43 | HTR2C |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ADORA1; ESR1 |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| C00-D49: Neoplasms | Breast cancer | C50 | CYP19A1; FLT3; FLT3; CA9; IGF1R; CDK1; ESR1; ESR1; KDR; KDR; KDR |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | SRC; ESR1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1 |
| C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | AKT1; MET; FLT3; CA9; MMP2; SRC; IGF1R; PTK2; AURKB; HIF1A; MAPK1; MMP9; TP53; KDR; KDR; KDR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PLA2G1B; ABCC1; ALOX5 |
| NA: NA | Menopausal disorder | NA | ESR1 |
| N00-N99: Diseases of the genitourinary system | Bladder disease | N30-N32 | OPRD1 |
| C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1 |
| C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Generalized anxiety disorder | F32, F40-F42, F41.1 | HTR2C |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | CAMK2B; AKR1B1; PLA2G1B; ALOX5; ELANE; OPRD1; MMP3 |
| J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | ALOX5 |
| C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR |
| N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; ESR1 |
| N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1 |
| C00-D49: Neoplasms | Mesothelioma | C45 | PTK2 |
| C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR |